CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The international study CCTG MAC29 (OptimICE-pCR) is investigating whether treatment with immunotherapy versus observation in people with early-stage triple-negative breast cancer (TNBC) who had a good response after initial treatment with chemotherapy and immunotherapy is really necessary.
The investigators want to determine if observation after surgery is as effective as completing 6 more months of immunotherapy in TNBC patients who have completed standard treatment including immunotherapy before surgery, and who have had a good response.
The CCTG Pharmacy Network is actively seeking pharmacy representation for the following:
In 2024, the Canadian Cancer Statistics publication was developed in the form of a peer-reviewed article "Projected estimates of cancer in Canada in 2024” published in the Canadian Medical Association Journal (CMAJ).
The Canadian Cancer Society (CCS) is uniting with a team of 12 researchers and collaborators to lead one of the world’s largest randomized controlled clinical trials using fecal microbiota transplantation (FMT) to improve the effectiveness of the standard of care for advanced melanoma.
Another successful CCTG Spring Meeting of Participants ended with ~900 network members, international friends and sponsors contributing to sessions and workshops to propose new trials and review current portfolio of activities. It was hectic but also inspirational.
Findings from the CCTG PR13/RADICALS-HD study confirm that adding two years, compared to six months of hormone therapy delays prostate cancer spread in people who had surgery to remove the prostate followed by radiotherapy.
A longer follow-up from the PR13/RADICALS-RT international study confirms that having radiotherapy only if the cancer returns, as opposed to having it soon after surgery, is a better approach for most people.
